KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:KMPH
- CUSIP: N/A
- Web: www.kempharm.com
- Market Cap: $52.77 million
- Outstanding Shares: 14,657,000
- 50 Day Moving Avg: $3.09
- 200 Day Moving Avg: $3.79
- 52 Week Range: $2.45 - $5.40
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.57
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($2.68) per share
- Price / Book: -1.34
- EBIDTA: ($33,550,000.00)
- Return on Assets: -51.98%
- Debt-to-Equity Ratio: -2.34%
- Current Ratio: 8.40%
- Quick Ratio: 8.40%
- Average Volume: 72,061 shs.
- Beta: -1.28
- Short Ratio: 8.87
Frequently Asked Questions for KemPharm (NASDAQ:KMPH)
What is KemPharm's stock symbol?
KemPharm trades on the NASDAQ under the ticker symbol "KMPH."
How were KemPharm's earnings last quarter?
KemPharm, Inc. (NASDAQ:KMPH) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. View KemPharm's Earnings History.
When will KemPharm make its next earnings announcement?
Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?
4 equities research analysts have issued 12-month price objectives for KemPharm's shares. Their predictions range from $7.00 to $13.00. On average, they anticipate KemPharm's share price to reach $9.00 in the next year. View Analyst Ratings for KemPharm.
What are analysts saying about KemPharm stock?
Here are some recent quotes from research analysts about KemPharm stock:
- 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 10, 2017, 16:01 ET Date and time of production: August 10, 2017, 16:01 ET Target Price / Valuation Methodology: KemPharm – KMPH Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $7/share for KMPH, assuming a stable timeline for KemPharm’s lead products, KP415, KP201/IR and KP511/ER. Additionally, we assume a KP415 launch in 2020 and KP201/IR and KP511/ER launches in 2021. Our valuation assumes a generic launch against KP201/IR around 2031 and generic launches against KP415 and KP511/ER around 2032. This corresponds with the expiries of composition of matter patents, before any FDA term extensions, for all three products." (8/10/2017)
- 2. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (7/12/2017)
Who are some of KemPharm's key competitors?
Some companies that are related to KemPharm include Otonomy (OTIC), Ophthotech Corporation (OPHT), MEI Pharma (MEIP), Intec Pharma (NTEC), Affimed N.V. (AFMD), Dicerna Pharmaceuticals (DRNA), Zafgen (ZFGN), ADMA Biologics (ADMA), Lipocine (LPCN), ProNAi Therapeutics (SRRA), Aeglea BioTherapeutics (AGLE), Pfenex (PFNX), Ergomed PLC (ERGO), ImmuPharma PLC (IMM), Rexahn Pharmaceuticals (RNN), Applied Genetic Technologies Corporation (AGTC), Akari Therapeutics PLC (AKTX) and Flex Pharma (FLKS).
Who are KemPharm's key executives?
KemPharm's management team includes the folowing people:
- Travis C. Mickle Ph.D., Chairman of the Board, President, Chief Executive Officer
- Timothy J. Sangiovanni, Principal Accounting Officer, Vice President, Corporate Controller
- Gordon K. Johnson, Chief Business Officer
When did KemPharm IPO?
(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.
Who owns KemPharm stock?
KemPharm's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
DELAWARE STREET CAPITAL MASTER FUND, L.P.
(10.00%), Arete Wealth Advisors LLC (5.81%), Creative Planning (3.10%), C WorldWide Group Holding A S (2.61%), Vanguard Group Inc. (1.70%) and Federated Investors Inc. PA (1.09%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.
Who sold KemPharm stock? Who is selling KemPharm stock?
KemPharm's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Menta Capital LLC, Victory Capital Management Inc. and Creative Planning. View Insider Buying and Selling for KemPharm.
Who bought KemPharm stock? Who is buying KemPharm stock?
KemPharm's stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S and Arete Wealth Advisors LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.
How do I buy KemPharm stock?
Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is KemPharm's stock price today?
MarketBeat Community Rating for KemPharm (NASDAQ KMPH)MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of KemPharm stock can currently be purchased for approximately $3.60.
Consensus Ratings for KemPharm (NASDAQ:KMPH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$9.00 (150.00% upside)|
Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/11/2017||Canaccord Genuity||Reiterated Rating||Buy||$7.00||High|
|8/10/2017||Oppenheimer Holdings, Inc.||Set Price Target||Buy||$13.00||Medium|
|6/28/2017||Roth Capital||Initiated Coverage||Buy -> Buy||$8.00||High|
|5/15/2017||Royal Bank Of Canada||Reiterated Rating||Buy||$8.00||Medium|
Earnings History for KemPharm (NASDAQ:KMPH)Earnings History by Quarter for KemPharm (NASDAQ KMPH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for KemPharm (NASDAQ:KMPH)
2017 EPS Consensus Estimate: ($2.78)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for KemPharm (NASDAQ:KMPH)
Insider Ownership Percentage: 22.80%Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Institutional Ownership Percentage: 40.01%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/14/2017||Delaware Street Capital Master||Major Shareholder||Buy||325,888||$3.27||$1,065,653.76|| |
|8/24/2017||Daniel L Cohen||EVP||Buy||5,000||$2.58||$12,900.00|| |
|8/24/2017||Gordon K Johnson||Insider||Buy||4,000||$2.60||$10,400.00|| |
|6/20/2017||Travis C Mickle||CEO||Buy||8,000||$3.45||$27,600.00|| |
|6/19/2017||R. Laduane Clifton||CFO||Buy||275||$3.30||$907.50|| |
|5/25/2017||Daniel L Cohen||EVP||Buy||2,500||$4.11||$10,275.00|| |
|3/31/2017||Daniel L Cohen||EVP||Buy||2,500||$4.48||$11,200.00|| |
|3/24/2017||R. Laduane Clifton||CFO||Buy||1,000||$4.24||$4,240.00|| |
|3/22/2017||Travis C Mickle||CEO||Buy||2,000||$4.10||$8,200.00|| |
|3/20/2017||David S Tierney||Director||Buy||1,000||$4.20||$4,200.00|| |
|11/30/2016||Daniel L Cohen||EVP||Buy||5,000||$3.50||$17,500.00|| |
|9/6/2016||Daniel L Cohen||EVP||Buy||10,000||$4.75||$47,500.00|| |
|8/17/2016||Travis C Mickle||CEO||Buy||5,000||$4.95||$24,750.00|| |
|3/29/2016||Travis C Mickle||CEO||Buy||2,450||$14.57||$35,696.50|| |
Headline Trends for KemPharm (NASDAQ:KMPH)
Latest Headlines for KemPharm (NASDAQ:KMPH)
|KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate|
finance.yahoo.com - September 21 at 12:29 PM
|KemPharm, Inc. (KMPH) Earns Buy Rating from Canaccord Genuity|
www.americanbankingnews.com - September 17 at 10:22 PM
|KemPharm, Inc. (KMPH) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - September 16 at 3:10 AM
|KemPharm, Inc. (KMPH) Major Shareholder Delaware Street Capital Master Acquires 325,888 Shares|
www.americanbankingnews.com - September 15 at 4:30 PM
|Astellas, KMPH, SRNE To Face FDA, ALXN Trims Workforce, ALDX Soars On Trial Data|
www.rttnews.com - September 13 at 3:33 AM
|KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA|
finance.yahoo.com - September 13 at 3:33 AM
|KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference|
finance.yahoo.com - September 1 at 1:55 AM
|KemPharm, Inc. (KMPH) Insider Buys $10,400.00 in Stock|
www.americanbankingnews.com - August 25 at 8:54 PM
|KemPharm, Inc. (KMPH) EVP Daniel L. Cohen Buys 5,000 Shares|
www.americanbankingnews.com - August 25 at 8:54 PM
|KemPharm, Inc. (KMPH) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - August 22 at 2:58 AM
|KemPharm, Inc. (KMPH) Expected to Announce Earnings of -$0.69 Per Share|
www.americanbankingnews.com - August 21 at 6:14 AM
|KemPharm, Inc. (KMPH) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.|
www.americanbankingnews.com - August 13 at 6:32 PM
|KemPharm (KMPH) Announces Prelim. Results from KP415 Pharmacokinetic Single and Multiple Dose Trial|
www.streetinsider.com - August 12 at 1:54 AM
|KemPharma reports 2Q loss|
www.cnbc.com - August 12 at 1:54 AM
|KemPharm, Inc. (NASDAQ:KMPH) Issues Quarterly Earnings Results|
www.americanbankingnews.com - August 11 at 5:16 PM
|KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial|
finance.yahoo.com - August 11 at 5:49 AM
|KemPharm, Inc. Reports Second Quarter 2017 Results|
finance.yahoo.com - August 11 at 5:49 AM
|KemPharm's (NASDAQ:KMPH) "Buy" Rating Reaffirmed at Canaccord Genuity|
www.americanbankingnews.com - August 10 at 6:26 PM
|KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety|
finance.yahoo.com - August 8 at 7:59 PM
|KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference|
finance.yahoo.com - August 3 at 11:31 PM
|Zacks: Analysts Expect KemPharm, Inc. (KMPH) Will Post Earnings of -$0.63 Per Share|
www.americanbankingnews.com - August 3 at 7:26 AM
|KemPharm, Inc. to Report Second Quarter 2017 Results|
finance.yahoo.com - August 2 at 2:46 AM
|KemPharm, Inc. (NASDAQ:KMPH) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 28 at 11:21 AM
|Zacks: Brokerages Expect KemPharm, Inc. (KMPH) Will Announce Earnings of -$0.63 Per Share|
www.americanbankingnews.com - July 11 at 6:14 PM
|KemPharm, Inc. (KMPH) Lowered to "Strong Sell" at ValuEngine|
www.americanbankingnews.com - July 8 at 10:10 PM
|KemPharm, Inc. (KMPH) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - July 3 at 12:04 PM
|KemPharm, Inc. (KMPH) Now Covered by Roth Capital|
www.americanbankingnews.com - July 2 at 3:08 PM
|KemPharm, Inc. (KMPH) Lifted to "Sell" at ValuEngine|
www.americanbankingnews.com - July 1 at 8:08 PM
|KemPharm (KMPH) Announced Two Advances Involving its Prodrug Development Pipeline to Treat ADHD|
www.streetinsider.com - June 30 at 12:52 AM
|KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline|
finance.yahoo.com - June 30 at 12:51 AM
|KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate|
finance.yahoo.com - June 28 at 7:45 PM
|KemPharm (KMPH) Granted First Patent for KP746|
www.streetinsider.com - June 26 at 8:05 PM
|KemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone|
finance.yahoo.com - June 26 at 8:05 PM
|KemPharm, Inc. (KMPH) CEO Buys $27,600.00 in Stock|
www.americanbankingnews.com - June 21 at 1:25 PM
|KemPharm, Inc. (KMPH) Expected to Post Earnings of -$0.63 Per Share|
www.americanbankingnews.com - June 15 at 6:28 PM
|KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids|
finance.yahoo.com - June 9 at 9:20 AM
|KemPharm Announces Addition to Leadership Team|
finance.yahoo.com - June 1 at 7:51 AM
|KemPharm Inc (KMPH) Lowered to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - May 28 at 5:56 PM
|Daniel L. Cohen Purchases 2,500 Shares of KemPharm Inc (KMPH) Stock|
www.americanbankingnews.com - May 26 at 8:29 PM
|Q2 2017 EPS Estimates for KemPharm Inc Reduced by Oppenheimer Holdings (KMPH)|
www.americanbankingnews.com - May 15 at 7:46 AM
|FY2021 EPS Estimates for KemPharm Inc (KMPH) Cut by Analyst|
www.americanbankingnews.com - May 12 at 6:56 PM
|KemPharm Inc (KMPH) Announces Quarterly Earnings Results|
www.americanbankingnews.com - May 11 at 7:36 PM
|KemPharm Inc (KMPH) Given a $13.00 Price Target by Oppenheimer Holdings Inc. Analysts|
www.americanbankingnews.com - May 11 at 2:56 PM
|KemPharma reports 1Q loss|
www.cnbc.com - May 10 at 6:06 PM
|KemPharm, Inc. Reports First Quarter 2017 Results|
finance.yahoo.com - May 10 at 6:06 PM
|Investor Network: KemPharm, Inc. to Host Earnings Call|
finance.yahoo.com - May 10 at 1:04 PM
|KemPharm Inc (KMPH) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - May 5 at 12:46 AM
|KemPharm (KMPH) Receiving Somewhat Favorable Press Coverage, Report Finds|
www.americanbankingnews.com - May 4 at 2:18 PM
|KemPharm Inc (KMPH) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - May 4 at 1:17 AM
|Zacks Investment Research Downgrades KemPharm Inc (KMPH) to Hold|
www.americanbankingnews.com - May 4 at 1:16 AM
KemPharm (KMPH) Chart for Friday, September, 22, 2017